Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical
Company pioneering novel cancer therapies and dedicated to the discovery,
development, and commercialization of novel first-in-class drugs for the
treatment of cancer and other diseases. Karyopharm's Selective Inhibitor
of Nuclear Export (SINE) compounds function by binding with and inhibiting
the nuclear export protein XPO1.